In patients undergoing percutaneous coronary intervention (PCI), who did not receive P2Y 12 inhibitor pretreatment, the optimal timing of P2Y 12 inhibitor loading dose remains debated. We sought to examine whether the choice of administration of the clopidogrel loading dose before or after the start of PCI had an impact on periprocedural complications, including bleeding. 
P
ercutaneous coronary intervention (PCI) is a key treatment of coronary artery disease both in stable and unstable situations. 1 To prevent periprocedural and postprocedural complications of PCI, adjunctive antiplatelet therapy by a P2Y 12 antagonist is required. 2 Although pretreatment by a loading dose (LD) of P2Y 12 inhibitor before PCI has been common for years, recent studies and meta-analyses suggest no clear benefit in favor of pretreatment. [3] [4] [5] In patients without pretreatment, no data are available about the appropriate timing of the LD administration, before or after the start of the PCI. This is a practical, daily issue for the interventional community, especially for patients treated with clopidogrel-a prodrug with a delayed onset of action because inappropriate timing could have clinical relevance. 6 The CHAMPION PHOENIX trial (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) was a double-blind, double-dummy, randomized controlled trial comparing cangrelor-the first intravenous P2Y 12 inhibitor-with clopidogrel in both elective and urgent situations. [7] [8] [9] The study demonstrated a benefit in favor of cangrelor in terms of reducing periprocedural ischemic complications. The study protocol stated that the clopidogrel LD could be administered before or after the start of PCI at a dose of 300 or 600 mg, at the discretion of the investigator. Pretreatment with clopidogrel before randomization was not permitted per protocol.
We examined whether clopidogrel loading before (early load [EL]) or after (late load [LL] ) the start of PCI impacted the rate of periprocedural complications or the beneficial effects of cangrelor.
METHODS

Study Design
The CHAMPION PHOENIX trial was a double-blind, doubledummy, randomized controlled trial comparing cangrelor with placebo in addition to clopidogrel in the setting of PCI. The design, rationale, and results have been published previously. 8 It recruited a total of 11 145 P2Y 12 inhibitornaive patients referred for PCI, whether for stable angina, non-ST-segment-elevation acute coronary syndromes, or ST-segment-elevation myocardial infarction (STEMI), randomized to be treated either by cangrelor bolus and infusion or clopidogrel in addition to an infusion of a placebo. In the cangrelor arm (ie, patients receiving infusion of cangrelor+clopidogrel), patients received, either before or after the start of PCI, a first series of capsules containing a placebo and at the end of the cangrelor infusion, a second series containing 600 mg of clopidogrel. In the placebo arm (ie, patients receiving infusion of placebo+clopidogrel), patients received a first series of capsules containing clopidogrel before or after the start of PCI and a second series containing placebo at the end of the placebo infusion. Investigators had the choice of clopidogrel LD of either 300 or 600 mg and the timing of the LD administration either before or after the start of PCI. The protocol received approval from the institutional review board. The data of the CHAMPION PHOENIX trial and of this analysis are available from the corresponding author on reasonable request.
EL was defined as clopidogrel administration before guidewire insertion indicating the start of the PCI, whereas LL was defined as clopidogrel administration after guidewire insertion.
Study Patients
Patients were eligible for recruitment in the CHAMPION PHOENIX trial if they required PCI, were a minimum of 18 years old, and were not pregnant. Every patient provided written informed consent. In addition, exclusion criteria included treatment by a P2Y 12 inhibitor within 7 days before randomization, eptifibatide or tirofiban use within 12 hours, abciximab use within 7 days, or any fibrinolytic therapy within 12 hours.
In this analysis, outcomes of patients randomized to the placebo arm (ie, received only clopidogrel) were analyzed according to the timing of clopidogrel administration and compared with the patients in the cangrelor+clopidogrel group.
Study Treatments
Loading and maintenance dose of aspirin, maintenance dose of clopidogrel or any P2Y 12 inhibitor, arterial access and sheath management, as well as the choice of periprocedural anticoagulant (unfractionated heparin, bivalirudin, low-molecular-weight heparin, or fondaparinux) were left to the discretion of the investigators with respect to local standard practices. GP IIb/IIIa (glycoprotein IIb/IIIa) inhibitors were allowed only as bailout therapy during PCI in case of complications defined as new or persistent thrombus formation, slow or no reflow, side-branch compromise, dissection, or distal embolization.
Outcomes
In this analysis, outcomes from the main CHAMPION PHOENIX trial were used. Briefly, all-cause death, myocardial infarction (MI), ischemia-driven revascularization, or stent thrombosis
WHAT IS KNOWN
• Pretreatment with a P2Y 12 inhibitor is no longer recommended before percutaneous coronary intervention.
• Cangrelor successfully reduces periprocedural outcomes as compared with clopidogrel.
WHAT THE STUDY ADDS
• In P2Y 12 -naive patients undergoing percutaneous coronary intervention, the timing of the loading dose before or after the start of the percutaneous coronary intervention is not associated with different periprocedural ischemic or hemorrhagic outcomes.
• The benefit of cangrelor remains consistent over the entire population.
(ST) were analyzed at 48 hours post-randomization and combined to provide the primary efficacy outcome; ST at 48 hours was a prespecified key secondary outcome. Safety outcomes at 48 hours included Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) severe, moderate, and mild bleeding, as well as Thrombolysis in MI and Acute Catheterization and Urgent Intervention Triage definitions, and transfusions. The key safety outcome from the main study was GUSTO severe bleeding, but because this rate was low, GUSTO severe and moderate bleeding rates were combined to provide a larger number of events. The Duke Clinical Research Institute Clinical Events Committee adjudicated the efficacy end points occurring in the first 30 days after randomization. The definitions used by the Clinical Events Committee are detailed in the original article. 8 Safety outcomes were not adjudicated.
Statistical Analyses
Analyses were performed on the population of patients who underwent PCI and received the study treatment, defined as the modified intention-to-treat population. Continuous variables are summarized as medians and quartiles or as means±SD, as appropriate, and were compared using the Student t test or Wilcoxon rank-sum test, accordingly. Categorical variables were presented as rate (%) and compared by the χ 2 or Fisher exact test, as appropriate. Interaction between the treatment and different subgroups on end point events was tested using logistic regression. Adjustments were performed using age, sex, weight, race, geographic origin (US/non-US origin), diabetes mellitus, current smoking, stroke/transient ischemic attack, prior MI, prior PCI, previous coronary artery bypass graft, peripheral artery disease, heart failure, indication of PCI (STEMI, non-STEMI, and stable angina), baseline cardiac marker positive status, clopidogrel LD choice, prior GP IIb/IIIa use, multivessel disease, number of vessels with >50% stenosis, bivalirudin, stent type, procedure duration, total stents placed, and total stent length. Selection of these covariates for adjustment in regression analyses was based on both clinical importance and statistical significance of differential distribution in comparison groups and in relationship to the end points.
The numbers (%) of patients within each subpopulation (EL versus LL) were summarized by treatment group. The primary efficacy analysis was conducted on the composite incidence rate of Clinical Events Committee-adjudicated all-cause mortality, MI, ischemia-driven revascularization, or ST in the 48 hours after randomization. All summaries and statistical analyses were performed using SAS, version 9.3 (Cary, NC).
RESULTS
Population
From the 11 145 patients recruited in the trial, the modified intention-to-treat population comprised 10 942 patients, including 5439 patients in the placebo (clopidogrel only) arm. Among these, 3442 received EL (63.3%) and 1997 LD (37.7%; Figure 1 ). EL was more frequently used in STEMI patients (83.8%) and non-ST-segment-elevation acute coronary syndromes (72.1%) than in stable patients (54.0%), whereas patients receiving an LL were older and more likely to be treated in the United States (80.5% versus 12.2% in the EL group; P<0.0001). An LD of 600 mg was more frequently used in the LL than in the EL group (97.5% versus 60.7%, respectively; P<0.0001).
Demographic characteristics and other baseline factors for the EL and LL groups are presented in Table 1 . Median time for EL was 5 minutes before PCI, whereas the LL group received clopidogrel a median 20 minutes after the start of PCI. Figure 2 represents the distribution of the timing of clopidogrel LD according to the dose given (300 mg, 600 mg, and all doses). Procedural characteristics are presented in Table 2 .
Efficacy Outcomes
There was no difference in the incidence of the primary outcome between patients receiving EL versus LL (6 Figure 3 . Overall, the benefit of cangrelor in reducing the composite primary outcome was consistent across both the EL and 
Safety Outcomes
Before adjustment, the rate of GUSTO severe and moderate bleeding was low and similar in the EL and LL groups (0.5% versus 0.4%, respectively; P=0.25); there was no difference between cangrelor and clopidogrel regarding the primary safety outcome of GUSTO 25 ). However, the rate of any GUSTO bleeding was lower in the clopidogrel-only groups, mainly driven by the rate of mild bleeding, but there was no significant interaction between EL and LL groups (interaction P=0.39). Results were similar regarding bleeding rates using the Thrombolysis in MI definition or frequency of transfusions ( Figure 5 ).
DISCUSSION
In a nonrandomized comparison of the control group of the CHAMPION PHOENIX trial consisting of patients undergoing urgent or elective PCI treated with clopidogrel but who did not receive P2Y 12 pretreatment, we observed that rates of periprocedural complications were similar in patients receiving clopidogrel before (EL) or after (LL) the start of PCI.
Several studies have questioned the benefit of P2Y 12 inhibitor pretreatment in stable angina, as well as in patients with acute coronary syndromes.
3,10-16 As a consequence, pretreatment with P2Y 12 inhibitors is not recommended on a systematic basis, 2,17 and a substantial proportion of patients do not receive pretreatment before PCI. In STEMI patients, even though one may intuitively expect a benefit, 5 pretreatment is likely to be underused for logistical reasons. Many patients might, therefore, not receive the oral P2Y 12 inhibitor early before angiography.
For those patients, there are no data on the best timing of P2Y 12 inhibitor LD administration (before or after PCI). This is a particular concern for patients treated with clopidogrel-a drug with a slow onset of action.
In stable patients, previous studies have examined the impact of scheduled clopidogrel pretreatment hours before the procedure, but no data are available comparing loading immediately before or shortly after the start of PCI. 3, 18 Similarly, in unstable patients, the potential benefit of P2Y 12 pretreatment has been widely studied leading to contradictory conclusions. 4, 5, 10, 13, 14, 19, 20 However, no data are available for the best timing of P2Y 12 inhibitor LD in the case of nonpretreated patients.
For those reasons, the control group of CHAMPION PHOENIX represents a unique opportunity to analyze the effect of EL versus LL of clopidogrel in patients who did not receive P2Y 12 inhibitor pretreatment. Our observation suggests that the clopidogrel LD can be administered either before or after the start of the PCI with no differences in terms of clinical outcomes.
One possible explanation for the lack of difference between the groups pertains to the onset of action of clopidogrel. Indeed, some studies have demonstrated that an LD of clopidogrel can achieve effective platelet inhibition at best within 3 hours, although ≤6 or 24 hours 6, 21 ; with median times for LD differing by only 25 minutes in our analysis (5 minutes before the start of PCI in EL, 20 after in LL), the absence of impact on outcomes seems logical. Likewise, in this study, the benefit of cangrelor was consistent regardless of the timing or the dose of clopidogrel load. Cangrelor is an intravenous P2Y 12 antagonist with immediate onset of action 8, 9, [22] [23] [24] allowing sufficient platelet inhibition to avoid periprocedural PCI complications, whereas clopidogrel-a prodrug-has not yet been metabolized. There was no impact of LD timing in terms of bleeding events. Given the low number of events, however, these observations should be made with caution because they may reflect type II error.
Independently of the impact on outcomes, early and late loading carry different advantages and inconveniences. In early loading, drugs are administered before angiography with no indication of the coronary anatomy; therefore, if an emergent surgical treatment is indicated, it would be impossible to reverse the action of the drug. In addition, unstable patients frequently suffer from vomiting before revascularization, and it is sometimes difficult to ascertain whether the oral dose is likely to be fully absorbed. On the contrary, the administration of a late loading to a patient lying on the intervention table is difficult in practice. Finally, if the duration of the PCI is too long, the LL could be delayed for hours without potential benefit. This analysis has a number of limitations. First, it is a subgroup, post hoc analysis of a larger trial designed for other purposes. Next, the rates of bleeding events are low. Clopidogrel LD choice and timing of administration were neither randomized nor blinded. Given the modest time difference between the 2 groups and the slow onset of action of clopidogrel, our findings cannot be extrapolated to longer time differences or to more potent and faster acting drugs, such as ticagrelor or prasugrel. Safety outcomes were not adjudicated. Data on variables potentially modifying clopidogrel absorption, such as morphine administration or vomiting after clopidogrel intake, were not captured. Finally, the distribution of EL and LL was not balanced in terms of stable and unstable patients with EL being more frequent in patients with acute coronary syndromes and LL more frequent in patients with stable angina. Because the rate of events is different among these groups, it may have affected the unadjusted outcomes, although the adjusted analysis accounted for, among other factors, clinical presentation. Finally, only clopidogrel was available in the CHAMPION study, and it is, therefore, possible that the use of more potent drugs, with faster onset of action, might have led to different results.
In conclusion, in the CHAMPION PHOENIX trial, in patients not pretreated with clopidogrel, periprocedural PCI complication rates, including bleeding, were similar regardless of the timing of the clopidogrel LD in relation to the start of PCI. The benefit of cangrelor over clopidogrel in reducing PCI complications and its impact on bleeding were consistent regardless of the timing of the clopidogrel LD.
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